查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2085495

藥物發現技術市場：2026-2032年全球市場預測（按藥物類型、檢測方法、技術平台、應用和最終用戶分類）

Drug Discovery Technologies Market by Drug Type, Assay Techniques, Technology Platforms, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，藥物發現技術市場將成長至 1,458 億美元，複合年成長率為 11.00%。

主要市場統計數據
基準年 2025 701.9億美元
預計年份：2026年 775.9億美元
預測年份 2032 1458億美元
複合年成長率 (%) 11.00%

藥物發現技術正在重塑製藥公司、生技公司、學術機構和受託研究機構識別、檢驗和開發候選治療藥物的方式。該領域的核心技術包括高通量篩檢、組合化學、基因組學、蛋白質組學、生物資訊學、結構生物學、細胞分析、類器官、微流體技術、實驗室自動化和In Silico模擬。這些工具透過改進標靶檢驗、先導化合物最佳化、毒性預測和基於生物標記的患者選擇，有助於降低研發失敗率。

該領域的戰略重要性也體現在其持續獲得監管機構批准的記錄上。美國食品藥物管理局（FDA）藥物評估與研究中心在2023年批准了55種新藥，2024年批准了50種，顯示市場對能夠將生物學發現轉化為有效療法的技術的需求仍然旺盛。隨著藥物研發管線在腫瘤學、免疫學、神經病學、罕見疾病和代謝性疾病等領域日益專業化，藥物發現平台也越來越受到重視，評估指標包括可重複性、轉化相關性、數據品質以及與臨床開發策略的整合性。

藥物發現領域的變革性變化

藥物研發的格局正從線性、化學主導的工作流程轉向資料豐富、生物學優先、平台驅動的研究模式。次世代定序、基於CRISPR的功能基因組學、單細胞分析、空間生物學和冷凍電子顯微鏡技術的進步，正在加深我們對疾病機制的理解，並使目標更容易被研究。同時，自動化實驗室和基於雲端的分析技術正在加速實驗週期，同時提高可審計性和跨機構協作效率。

人工智慧的累積影響

人工智慧如今正發揮著協同效應，滲透到各個領域，從標靶發現和蛋白質結構預測到分子設計、ADMET建模、文獻挖掘以及生物標記發現，這些都為臨床試驗提供了支持。 AlphaFold資料庫發布了超過2億個蛋白質的結構預測結果，充分展現了計算生物學如何以前所未有的規模擴展結構資訊的獲取。遺傳化學和機器學習模型也在幫助研究團隊更有效率地探索化學空間，儘管實驗檢驗仍然至關重要。

關鍵區域洞察：全球藥物研發中心

北美憑藉其龐大的生物製藥產業規模、創業投資生態系統、大學附屬醫療中心以及豐富的監管經驗，仍然是藥物研發技術的中心。美國在平台創新、轉化醫學和臨床階段生物技術公司的創建方面發揮主導作用，而加拿大則在人工智慧研究、結構生物學和公私合營的生命科學舉措表現出色。

關於策略聯盟的關鍵群體特定見解

東協正透過新加坡的生物醫學研究中心、馬來西亞和泰國的臨床研究能力以及全部區域不斷擴展的數位醫療基礎設施，加強其在支持藥物研發方面的作用。海灣合作理事會（GCC）正透過國家基因組計畫、對精準醫療的投資以及與醫院合作建構創新生態系統來提升研究能力，其中阿拉伯聯合大公國和沙烏地阿拉伯發揮主導作用。

來自影響市場動能的關鍵國家的洞察

美國是創業投資驅動的生物技術、符合FDA標準的研發策略、人工智慧藥物發現平台的全球領導者。加拿大以其在多倫多、蒙特婁和溫哥華的人工智慧研究生態系統而聞名，這得益於其在結構生物學和轉化醫學方面的優勢。墨西哥和巴西是拉丁美洲重要的臨床研究、生物製藥生產和學術合作市場，其中巴西擁有該地區最大的生命科學研究中心之一。

為行業領導者提供的實用建議

產業領導者應優先發展那些不僅能提升處理能力，還能提高轉化可靠性的藥物發現技術。投資應集中於整合體學、表現型篩檢、結構生物學、人工智慧建模和人類相關疾病模型的綜合平台。團隊在推進專案之前，也應建立明確的證據標準，用於標靶驗證、安全性風險評估和生物標記準備的評估。

調查方法和證據

本執行摘要基於檢驗研究，資料來源包括監管出版刊物、政府研究津貼資料、同行評審的科學文獻、公開資訊來源以及廣受認可的行業報告。主要指標包括新藥認證趨勢、公共研發項目、技術採納趨勢、區域創新基礎設施以及人工智慧、基因組學、結構生物學和轉化建模領域的科學進展。

結論：建構下一代藥物發現優勢

藥物發現技術正成為現代生物製藥研發競爭的核心。最強大的平台是將生物學見解、計算智慧、實驗檢驗和臨床應用相結合的平台。人工智慧正在加速藥物發現，但其價值取決於檢驗的資料集、可重複的檢測方法和嚴格的科學管治。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 藥物發現技術市場：依藥物類型分類

  • 生物製藥
  • 小分子藥物

第8章 藥物發現技術市場：依檢測方法分類

  • 結合試驗
  • 生化分析
  • 基於細胞的檢測
  • 報導基因分析

第9章 藥物發現技術市場：依技術平台分類

  • 計算建模
  • 高通量篩檢
  • 奈米科技
  • 藥物基因體學
  • 結構設計

第10章 藥物發現技術市場：依應用領域分類

  • 生物標記發現
  • 發現鉛
  • 臨床前和臨床開發
  • 目標識別與檢驗
  • 毒性測試

第11章 藥物發現技術市場：以最終用戶分類

  • 學術機構
  • 生技公司
  • 製藥公司

第12章 藥物發現技術市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第13章 藥物發現技術市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 藥物發現技術市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第16章：公司簡介

  • Abbott Laboratories, Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Bayer Healthcare AG
  • Bio-Rad Laboratories, Inc.
  • bioMerieux SA
  • Bristol-Myers Squibb Company
  • Covaris, LLC
  • Curia Global, Inc.
  • Elucidata Corporation
  • Eurofins Advinus Private Limited
  • Evotec SE
  • F. Hoffmann-La Roche Ltd.
  • GE Healthcare Ltd.
  • Gilead Sciences, Inc.
  • Horiba, Ltd.
  • Illumina, Inc.
  • IQVIA Inc.
  • Luminex Corporation by DiaSorin Group
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • PIRAMAL PHARMA LIMITED
  • Randox Laboratories Ltd.
  • Revolution Medicines, Inc.
  • Sanofi SA
  • Sygnature Discovery Limited
  • Syngene International Limited
  • Thermo FIsher Scientific Inc.
  • VWR International LLC
  • WuXi AppTec Co., Ltd.
Product Code: MRR-4348D129FA8B

The Drug Discovery Technologies Market is projected to grow by USD 145.80 billion at a CAGR of 11.00% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 70.19 billion
Estimated Year [2026] USD 77.59 billion
Forecast Year [2032] USD 145.80 billion
CAGR (%) 11.00%

Drug discovery technologies are reshaping how pharmaceutical, biotechnology, academic, and contract research organizations identify, validate, and advance therapeutic candidates. The landscape is anchored by high-throughput screening, combinatorial chemistry, genomics, proteomics, bioinformatics, structural biology, cell-based assays, organoids, microfluidics, laboratory automation, and in silico modeling. These tools help reduce attrition by improving target validation, lead optimization, toxicity prediction, and biomarker-driven patient selection.

The strategic importance of this landscape is reinforced by sustained regulatory productivity. The U.S. FDA Center for Drug Evaluation and Research approved 55 novel drugs in 2023 and 50 novel drugs in 2024, underscoring continued demand for technologies that can convert biological insight into approvable therapies. As drug pipelines become more specialized across oncology, immunology, neurology, rare diseases, and metabolic disorders, discovery platforms are increasingly judged by reproducibility, translational relevance, data quality, and integration with clinical development strategy.

Transformative Shifts in the Discovery Landscape

The drug discovery landscape is shifting from linear, chemistry-led workflows toward data-rich, biology-first, and platform-enabled research models. Advances in next-generation sequencing, CRISPR-based functional genomics, single-cell analysis, spatial biology, and cryo-electron microscopy are improving the understanding of disease mechanisms and target tractability. In parallel, automated laboratories and cloud-based analytics are accelerating experimental cycles while improving auditability and cross-site collaboration.

Another major shift is the move toward translationally relevant models. Organoids, organ-on-a-chip systems, induced pluripotent stem cell models, and patient-derived xenografts are being used to close the gap between in vitro assays and human biology. This transition is particularly important because late-stage clinical failure remains costly, often linked to inadequate efficacy or safety signals that were not detected early. Industry leaders are therefore prioritizing drug discovery technologies that generate decision-ready evidence rather than simply increasing screening volume.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is now a cumulative force across target discovery, protein structure prediction, molecular design, ADMET modeling, literature mining, and trial-enabling biomarker discovery. The release of AlphaFold protein structure predictions for more than 200 million proteins through the AlphaFold Database demonstrated how computational biology can expand access to structural insight at unprecedented scale. Generative chemistry and machine learning models are also helping teams explore chemical space more efficiently, although experimental validation remains essential.

The most durable impact of AI is not replacing scientific judgment but compressing iteration time. AI-enabled drug discovery platforms can prioritize targets, rank compounds, flag liabilities, and connect multi-omics data with disease phenotypes. The value is greatest when models are trained on high-quality, standardized, and traceable datasets, then validated through wet-lab assays. Organizations with integrated data governance, laboratory automation, and cross-functional scientific review are better positioned to turn AI outputs into drug discovery decisions that regulators, partners, and investors can trust.

Key Regional Insights: Global Discovery Hubs

North America remains a central hub for drug discovery technologies due to the scale of its biopharmaceutical industry, venture capital ecosystem, academic medical centers, and regulatory experience. The United States leads in platform innovation, translational medicine, and clinical-stage biotech creation, while Canada contributes strengths in AI research, structural biology, and public-private life science initiatives.

Europe combines scientific depth with coordinated research infrastructure, supported by Horizon Europe, which has a budget of EUR 95.5 billion for 2021-2027. Germany, France, the United Kingdom, Italy, and Spain maintain strong clusters in biologics, medicinal chemistry, and precision medicine. Asia-Pacific is expanding as China, India, Japan, South Korea, Australia, and ASEAN economies increase investment in biomanufacturing, genomics, clinical research, and digital health infrastructure. Latin America is gaining relevance through Brazil and Mexico's clinical research capacity and growing academic-industry collaboration.

The Middle East is investing in genomics, digital health, and research hospitals, particularly across Gulf economies seeking to diversify beyond hydrocarbons. Africa's opportunity is tied to population-scale genomics, infectious disease research, and regional clinical trial inclusion, although infrastructure, funding continuity, and workforce development remain critical constraints. Across all regions, the most competitive drug discovery ecosystems are those combining scientific talent, regulatory clarity, data infrastructure, and reliable access to capital.

Key Group Insights Across Strategic Alliances

ASEAN is strengthening its role in drug discovery support through Singapore's biomedical research base, Malaysia and Thailand's clinical research capabilities, and expanding digital health infrastructure across the region. The GCC is building research capacity through national genomics programs, precision medicine investments, and hospital-linked innovation ecosystems, with the United Arab Emirates and Saudi Arabia playing leading roles.

The European Union provides a harmonized policy and funding environment that supports cross-border research, clinical trial modernization, and data-sharing frameworks. BRICS economies are increasingly important because they combine large patient populations, manufacturing capabilities, and expanding R&D investment, although regulatory harmonization and intellectual property consistency vary by market. The G7 continues to dominate high-value innovation through established pharmaceutical research systems, advanced universities, and deep capital markets. NATO countries overlap significantly with major life science economies, and their strengths in cybersecurity, supply chain resilience, and advanced computing are increasingly relevant as drug discovery becomes more data-dependent.

Key Country Insights Shaping Market Momentum

The United States is the leading country for venture-backed biotechnology, FDA-facing development strategy, and AI-enabled discovery platforms. Canada is recognized for AI research ecosystems in Toronto, Montreal, and Vancouver, supported by strengths in structural biology and translational medicine. Mexico and Brazil are important Latin American markets for clinical research, biopharmaceutical manufacturing, and academic collaboration, with Brazil maintaining one of the region's largest life science research bases.

In Europe, the United Kingdom remains influential in genomics, academic spinouts, and regulatory science, while Germany leads in engineering, laboratory automation, and pharmaceutical manufacturing. France is expanding biocluster development and biotech financing, Italy contributes expertise in oncology, rare diseases, and manufacturing, and Spain is strengthening clinical research and translational medicine. Russia retains scientific capacity in chemistry and biomedical research, although international collaboration is affected by geopolitical constraints.

China is a major force in discovery, clinical development, biologics, and AI-enabled research, supported by large patient datasets and growing domestic innovation. India contributes medicinal chemistry, informatics, contract research, and cost-efficient scientific talent. Japan remains strong in precision medicine, regenerative medicine, and high-quality pharmaceutical R&D, while South Korea is advancing biologics, cell therapy, and digital health. Australia is valued for early-phase clinical trials, academic research quality, and a regulatory environment that supports rapid translational studies.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize discovery technologies that improve translational confidence rather than only increasing throughput. Investment should focus on integrated platforms combining omics, phenotypic screening, structural biology, AI modeling, and human-relevant disease models. Teams should also establish clear evidence thresholds for target validation, safety liability assessment, and biomarker readiness before advancing programs.

Executives should strengthen data governance, including metadata standards, model documentation, assay reproducibility metrics, and secure cloud architecture. Partnerships with academic centers, CROs, AI developers, and regional innovation clusters can accelerate capability building, but collaboration agreements should define data ownership, validation responsibilities, and regulatory documentation standards. Organizations that align discovery strategy with clinical feasibility, manufacturability, and reimbursement relevance will be better positioned to convert scientific innovation into durable pipeline value.

Research Methodology and Evidence Base

This executive summary is built on secondary research from verified public sources, including regulatory agency publications, government research funding data, peer-reviewed scientific literature, public disclosures, and recognized industry reports. Key indicators reviewed include novel drug approval activity, public R&D programs, technology adoption patterns, regional innovation infrastructure, and scientific advances in AI, genomics, structural biology, and translational models.

The methodology emphasizes triangulation across multiple credible sources to reduce bias and validate market direction. Qualitative assessment was applied to compare regional ecosystems, strategic alliances, country-level capabilities, and technology adoption drivers. The analysis focuses on decision-useful insights for executives, investors, research leaders, and commercial strategy teams operating in the drug discovery technologies market, while avoiding market sizing, market share, and forecasting claims.

Conclusion: Building the Next Discovery Advantage

Drug discovery technologies are becoming central to the competitiveness of modern biopharmaceutical R&D. The strongest platforms are those that connect biological insight, computational intelligence, experimental validation, and clinical translation. AI is accelerating discovery, but its value depends on validated datasets, reproducible assays, and disciplined scientific governance.

As regional ecosystems mature, opportunities will expand across North America, Europe, Asia-Pacific, Latin America, the Middle East, and Africa. Leaders that integrate automation, AI, human-relevant models, and collaborative networks will be best positioned to improve productivity, reduce attrition, and bring differentiated therapies to patients more efficiently.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Drug Discovery Technologies Market, by Drug Type

  • 7.1. Biologic Drugs
  • 7.2. Small-Molecule Drugs

8. Drug Discovery Technologies Market, by Assay Techniques

  • 8.1. Binding Assays
  • 8.2. Biochemical Assays
  • 8.3. Cell Based Assays
  • 8.4. Reporter Gene Assays

9. Drug Discovery Technologies Market, by Technology Platforms

  • 9.1. Computational Modeling
  • 9.2. High Throughput Screening
  • 9.3. Nanotechnology
  • 9.4. Pharmacogenomics
  • 9.5. Structure Based Design

10. Drug Discovery Technologies Market, by Application

  • 10.1. Biomarker Discovery
  • 10.2. Lead Discovery
  • 10.3. Preclinical & Clinical Development
  • 10.4. Target Identification & Validation
  • 10.5. Toxicology Testing

11. Drug Discovery Technologies Market, by End User

  • 11.1. Academic Institutions
  • 11.2. Biotechnology Firms
  • 11.3. Pharmaceutical Companies

12. Drug Discovery Technologies Market, by Region

  • 12.1. Asia-Pacific
  • 12.2. North America
  • 12.3. Latin America
  • 12.4. Europe
  • 12.5. Middle East
  • 12.6. Africa

13. Drug Discovery Technologies Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Drug Discovery Technologies Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Concentration Analysis, 2025
    • 15.1.1. Concentration Ratio (CR)
    • 15.1.2. Herfindahl Hirschman Index (HHI)
  • 15.2. Recent Developments & Impact Analysis, 2025
  • 15.3. Product Portfolio Analysis, 2025
  • 15.4. Benchmarking Analysis, 2025

16. Company Profiles

  • 16.1. Abbott Laboratories, Inc.
  • 16.2. Amgen Inc.
  • 16.3. AstraZeneca PLC
  • 16.4. Bayer Healthcare AG
  • 16.5. Bio-Rad Laboratories, Inc.
  • 16.6. bioMerieux SA
  • 16.7. Bristol-Myers Squibb Company
  • 16.8. Covaris, LLC
  • 16.9. Curia Global, Inc.
  • 16.10. Elucidata Corporation
  • 16.11. Eurofins Advinus Private Limited
  • 16.12. Evotec SE
  • 16.13. F. Hoffmann-La Roche Ltd.
  • 16.14. GE Healthcare Ltd.
  • 16.15. Gilead Sciences, Inc.
  • 16.16. Horiba, Ltd.
  • 16.17. Illumina, Inc.
  • 16.18. IQVIA Inc.
  • 16.19. Luminex Corporation by DiaSorin Group
  • 16.20. Merck & Co., Inc.
  • 16.21. Novartis AG
  • 16.22. Pfizer Inc.
  • 16.23. PIRAMAL PHARMA LIMITED
  • 16.24. Randox Laboratories Ltd.
  • 16.25. Revolution Medicines, Inc.
  • 16.26. Sanofi S.A.
  • 16.27. Sygnature Discovery Limited
  • 16.28. Syngene International Limited
  • 16.29. Thermo FIsher Scientific Inc.
  • 16.30. VWR International LLC
  • 16.31. WuXi AppTec Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ASSAY TECHNIQUES, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ASSAY TECHNIQUES, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BIOLOGIC DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BIOLOGIC DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BIOLOGIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL SMALL-MOLECULE DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL SMALL-MOLECULE DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL SMALL-MOLECULE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ASSAY TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL BINDING ASSAYS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL BINDING ASSAYS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL BINDING ASSAYS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL BIOCHEMICAL ASSAYS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL BIOCHEMICAL ASSAYS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL BIOCHEMICAL ASSAYS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CELL BASED ASSAYS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CELL BASED ASSAYS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CELL BASED ASSAYS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL REPORTER GENE ASSAYS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL REPORTER GENE ASSAYS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL REPORTER GENE ASSAYS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL COMPUTATIONAL MODELING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL COMPUTATIONAL MODELING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL COMPUTATIONAL MODELING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL HIGH THROUGHPUT SCREENING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL HIGH THROUGHPUT SCREENING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL HIGH THROUGHPUT SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL NANOTECHNOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL NANOTECHNOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL NANOTECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL STRUCTURE BASED DESIGN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL STRUCTURE BASED DESIGN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL STRUCTURE BASED DESIGN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL BIOMARKER DISCOVERY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL BIOMARKER DISCOVERY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL BIOMARKER DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL LEAD DISCOVERY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL LEAD DISCOVERY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL LEAD DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL PRECLINICAL & CLINICAL DEVELOPMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL PRECLINICAL & CLINICAL DEVELOPMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL PRECLINICAL & CLINICAL DEVELOPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL TARGET IDENTIFICATION & VALIDATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL TARGET IDENTIFICATION & VALIDATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL TARGET IDENTIFICATION & VALIDATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL TOXICOLOGY TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL TOXICOLOGY TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL TOXICOLOGY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ACADEMIC INSTITUTIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ACADEMIC INSTITUTIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ACADEMIC INSTITUTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL BIOTECHNOLOGY FIRMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL BIOTECHNOLOGY FIRMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL BIOTECHNOLOGY FIRMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL PHARMACEUTICAL COMPANIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL PHARMACEUTICAL COMPANIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL PHARMACEUTICAL COMPANIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. ASIA-PACIFIC DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 66. ASIA-PACIFIC DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 67. ASIA-PACIFIC DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ASSAY TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 68. ASIA-PACIFIC DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 69. ASIA-PACIFIC DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 70. ASIA-PACIFIC DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 71. NORTH AMERICA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 72. NORTH AMERICA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 73. NORTH AMERICA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ASSAY TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 74. NORTH AMERICA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 75. NORTH AMERICA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 76. NORTH AMERICA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 77. LATIN AMERICA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 78. LATIN AMERICA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 79. LATIN AMERICA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ASSAY TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 80. LATIN AMERICA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 81. LATIN AMERICA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 82. LATIN AMERICA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPE DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ASSAY TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 86. EUROPE DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 89. MIDDLE EAST DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 90. MIDDLE EAST DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. MIDDLE EAST DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ASSAY TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 92. MIDDLE EAST DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 93. MIDDLE EAST DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 94. MIDDLE EAST DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 95. AFRICA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 96. AFRICA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. AFRICA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ASSAY TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 98. AFRICA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 99. AFRICA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 100. AFRICA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. ASEAN DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 103. ASEAN DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 104. ASEAN DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ASSAY TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 105. ASEAN DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 106. ASEAN DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 107. ASEAN DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 108. GCC DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 109. GCC DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. GCC DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ASSAY TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 111. GCC DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 112. GCC DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 113. GCC DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPEAN UNION DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPEAN UNION DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPEAN UNION DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ASSAY TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPEAN UNION DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPEAN UNION DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPEAN UNION DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 120. BRICS DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 121. BRICS DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. BRICS DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ASSAY TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 123. BRICS DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 124. BRICS DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 125. BRICS DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 126. G7 DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 127. G7 DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. G7 DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ASSAY TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 129. G7 DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 130. G7 DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 131. G7 DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 132. NATO DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 133. NATO DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. NATO DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ASSAY TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 135. NATO DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 136. NATO DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 137. NATO DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. UNITED STATES DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 140. UNITED STATES DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. UNITED STATES DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ASSAY TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 142. UNITED STATES DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 143. UNITED STATES DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 144. UNITED STATES DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 145. CANADA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 146. CANADA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. CANADA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ASSAY TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 148. CANADA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 149. CANADA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 150. CANADA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 151. MEXICO DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 152. MEXICO DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. MEXICO DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ASSAY TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 154. MEXICO DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 155. MEXICO DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 156. MEXICO DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 157. BRAZIL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 158. BRAZIL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 159. BRAZIL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ASSAY TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 160. BRAZIL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 161. BRAZIL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 162. BRAZIL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 163. UNITED KINGDOM DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 164. UNITED KINGDOM DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. UNITED KINGDOM DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ASSAY TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 166. UNITED KINGDOM DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 167. UNITED KINGDOM DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 168. UNITED KINGDOM DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 169. GERMANY DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 170. GERMANY DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 171. GERMANY DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ASSAY TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 172. GERMANY DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 173. GERMANY DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 174. GERMANY DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 175. FRANCE DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 176. FRANCE DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 177. FRANCE DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ASSAY TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 178. FRANCE DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 179. FRANCE DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 180. FRANCE DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 181. RUSSIA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 182. RUSSIA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. RUSSIA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ASSAY TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 184. RUSSIA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 185. RUSSIA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 186. RUSSIA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 187. ITALY DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 188. ITALY DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 189. ITALY DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ASSAY TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 190. ITALY DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 191. ITALY DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 192. ITALY DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 193. SPAIN DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 194. SPAIN DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 195. SPAIN DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ASSAY TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 196. SPAIN DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 197. SPAIN DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 198. SPAIN DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 199. CHINA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 200. CHINA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 201. CHINA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ASSAY TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 202. CHINA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 203. CHINA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 204. CHINA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 205. INDIA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 206. INDIA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 207. INDIA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ASSAY TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 208. INDIA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 209. INDIA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 210. INDIA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 211. JAPAN DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 212. JAPAN DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. JAPAN DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ASSAY TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 214. JAPAN DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 215. JAPAN DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 216. JAPAN DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 217. AUSTRALIA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 218. AUSTRALIA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 219. AUSTRALIA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ASSAY TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 220. AUSTRALIA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 221. AUSTRALIA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 222. AUSTRALIA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 223. SOUTH KOREA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 224. SOUTH KOREA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 225. SOUTH KOREA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ASSAY TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 226. SOUTH KOREA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 227. SOUTH KOREA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 228. SOUTH KOREA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)